drugset / Trial / NCT04141904

Tofacitinib in Depression (TIDE)

NCT04141904

RandomizedParallel-groupQuadruple-blindBasic science

Summary

This study will test whether 7-10 day administration of the anti-inflammatory drug, tofacitinib, has positive effects on people experiencing treatment-resistant depression compared to placebo.

Timeline

Start
2020-02-10
Primary completion
2022-05-23
Completion
2022-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule 5 mg